Osteoarthritis (OA) is a common and disabling disease. Because of improved treatment of chronic diseases and lower mortality from infectious diseases, the US population is aging, and older Americans are living with disabling conditions, including hip OA. The projected number of older adults with arthritis or other chronic musculoskeletal joint symptoms is expected to nearly double, from 21.4 million in 2005 to 41.1 million by 2030. The burden of hip OA is increasing due to the aging population and the obesity crisis; as a result, the need for total hip arthroplasty (THA) is expected to grow 174%, to 572,000 primary THAs per year by 2030 in the United States. Prior projections appear to have underestimated the actual number of primary and revision THAs that are in demand.
From the Hip Preservation Center, Department of Orthopedic Surgery, Rush Medical College, Rush University Medical Center, Chicago, IL (Dr. Nho), the Center for Economic Evaluation in Medicine, Washington University School of Medicine, St. Louis, MO (Dr. Kymes), the University of Iowa and the Iowa City VA Medical Center, Iowa City, IA (Dr. Callaghan), and Boston University School of Medicine, Boston, MA (Dr. Felson).
Dr. Nho or an immediate family member serves as a paid consultant to Stryker, Pivot Medical, and Össur, and has received research or institutional support from Arthrex, ConMed Linvatec, Smith & Nephew, DJ Orthopaedics, Miomed, Athletico, Stryker, Pivot Medical, and AlloSource. Dr. Callaghan or an immediate family member has received royalties from DePuy. Dr. Felson or an immediate family member serves as a paid consultant to Knee Creations. Neither Dr. Kymes nor any immediate family member has received anything of value from or has stock or stock options held in a commercial company or institution related directly or indirectly to the subject of this article.